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Estrogens are clearly carcinogenic in humans and rodents but the mechanisms by which these
hormones induce cancer are only partially understood. Stimulation of cell proliferation and gene
expression by binding to the estrogen receptor is one important mechanism in hormonal
carcinogenesis; however, estrogenicity is not sufficient to explain the carcinogenic activity of all
estrogens because some estrogens are not carcinogenic. Estrogens are nonmutagenic in many
assays but exhibit specific types of genotoxic activity under certain conditions. We have studied
extensively the mechanisms by which estrogens induce neoplastic transformation in a model in
vitro system and our findings are summarized in this review. 17[-Estradiol (E2) and diethylstilbestrol
(DES) and their metabolites induce morphological and neoplastic transformation of Syrian
hamster embryo (SHE) cells that express no measurable levels of estrogen receptor. Treatment
of the cells with E2 or DES fails to induce DNA damage, chromosome aberrations and gene
mutations in SHE cells but results in numerical chromosome aberrations (aneuploidy) that could
arise from microtubule disruption or disfunction of mitotic apparatus. Estrogen-induced genotoxicity
is detected in cells following treatment with estrogen metabolites or following exogenous
metabolic activation of estrogens. The estrogens induce DNA adduct formation that is detected by
32P-postlabeling. Both aneuploidy induction and DNA damage caused by DNA adduct formation
correlate with the estrogen-induced cell transformation and may be important in hormonal
carcinogenesis. We propose that multiple effects of estrogens acting together cause genetic
alterations leading to cell transformation. Environ Health Perspect 105(Suppl 3):619-624 (1997)
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Estrogen use has been associated with an
increased risk for breast cancer and
endometrial cancers in women (1-4).
Various natural and synthetic estrogens
also induce mammary, pituitary, cervical,
uterine, and renal tumors in rodents (4-5).
Diethylstilbestrol (DES), a synthetic estro-
gen, is well known to be carcinogenic to
humans (6). The cellular and molecular
mechanism(s) whereby estrogen-induced
neoplastic events occur have not been fully
elucidated, but there is strong evidence
that estrogens are epigenetic carcinogens,
acting via a promoting effect related to
cellular proliferation, mediated through the
estrogen receptor (7-15). However, it has
been shown that estrogenic activity is not
sufficient to explain the carcinogenic activ-
ity in vivo and in vitro under certain exper-
imental conditions. Another mechanism,
related to mutagenic changes, has been
suggested in studies ofestrogen-induced
carcinogenesis (16-24).
The application ofcell cultures to study
carcinogenic mechanisms of chemical/
physical carcinogens can provide insights
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into the cellular and molecular mecha-
nisms ofcarcinogenesis, which is difficult
in whole-animal or human systems. We
have used Syrian hamster embryo (SHE)
fibroblast cell cultures as a model system to
study the ability of estrogens to directly
transform cells.
Morphological and
Neoplastic Transformation
in Vitroby Estrogens and
Estrogenlike Chemicals
Morphological and neoplastic transfor-
mation of SHE cells is induced by DES,
17,-estradiol (E2) and other estrogens.
We observed that DES and E2 induce
transformation of hamster cells that is
indistinguishable from that induced by
other chemical carcinogens such as
benzo[a]pyrene (19,25). Sarcomas are also
induced in Syrian hamsters in vivo follow-
ing subcutaneous injection of DES (26).
SHE cells do not express measurable levels
of estrogen receptor and estrogen treat-
ment is not mitogenic to the cells (27).
Thus, estrogenic activity ofthe compounds
can be excluded in this in vitro assay. The
cells do, however, have the ability to
metabolize estrogens (28,29), and the role
ofmetabolic activation in the carcinogene-
sis activity of estrogens in this model is
under investigation as discussed later.
The role ofmutagenesis in the neoplastic
transformation ofSHE cells by estrogens has
been studied extensively. We have demon-
strated that treatment of SHE cells with
DES or E2 induces cell transformation with-
out measurable gene mutations, unsched-
uled DNA synthesis (UDS) or structural
chromosome aberrations (19,20,23).
Under the same conditions, both estrogens
induce a specific type of genetic change,
i.e., aneuploidy. Chromosome losses and
gains are induced (20,23), suggesting a
nondisjunctional mechanism involved in
the transforming activity. Structural ana-
logues of DES have also been tested in
this cell transformation system (25,30).
Like DES, tetrafluorodiethylstilbestrol
(TF-DES) and dimethylstilbestrol (DMS)
induce morphological transformation of
SHE cells. The transformation frequency of
DMS is much less than that of DES and
TF-DES. Hexestrol (HEX) and dimethoxy-
diethylstilbestrol (DM-DES) do not trans-
form these cells. There is a good association
between the metabolic conversion of
DES analogues via a peroxidase-mediated
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oxidative pathway and their ability to
induce cell transformation. DES, DMS,
and TF-DES can all be metabolized by per-
oxidase. In contrast, HEX and DM-DES
are not metabolized via this pathway (25),
suggesting that DES metabolism is impor-
tant in its carcinogenicity. The peroxida-
tive-mediated metabolism of DES that
operates in SHE cells is also the major
pathway ofDES metabolism in the known
DES target tissue [e.g., adult (31) or fetal
uterus (32)] (25).
Treatment of SHE cells with DES in
the presence ofexogenous metabolic activa-
tion with rat liver postmitochondrial super-
natant (PMS) enhances morphological
transformation in a dose-dependent man-
ner (33). Exposure of SHE cells to DES
under the same conditions with exogenous
metabolic activation induces DNA damage
(determined by UDS) (21), and somatic
mutation at the Na+/K+-ATPase locus (33).
SHE cells peroxidatively metabolize DES to
cis,cis-dienestrol (J-dienestrol) (29), which
does not induce UDS by itself (21). More
,B-dienestrol is formed in cells treated in the
presence ofrat liver PMS.
P-Dienestrol can potentially form a phe-
noxyradical intermediate via a peroxidase-
mediated pathway, and this intermediate
maybind to DNAand induce UDS.
DES exhibits positive activity in
other cell transformation systems as well.
Fitzgerald et al. (34) demonstrated in the
BALB/c 3T3 cell transformation system
that DES displays transforming activity
with no measurable induction of gene
mutation at the Na+/K+-ATPase locus.
Transformation frequency of the cells is
enhanced by DES when treated with DES
in the presence of rat hepatocytes that are
freshly prepared. Rinehart et al. (35)
showed that chronic exposure to DES of
human endometrial stromal cells with a
temperature-sensitive SV40 large T antigen
induces a dose-dependent increase in the
immortalization of cells, which is deter-
mined by the ability to grow at the restric-
tive temperature. Moreover, the increase in
cell proliferation at the restrictive tempera-
ture is concurrent with alterations inp53 in
the cells. As immortalization is an impor-
tant step in the carcinogenesis process, and
immortalization of human cells may be
analogous to initiation ofrodent cells, DES
could act as an initiator in the carcinogenic
process ofhuman cells (35).
We have studied the ability ofestradiol
(E2) and different metabolites of E2 to
induce cell transformation. E2 metabolism
is similar in rats and in humans. E2 is
initially oxidized to estrone (E1), followed
by hydroxylations at positions C-2 and 16ac
that are mutually exclusive (5). The prin-
cipal products of 16a-hydroxylation are
16ax-hydroxyestrone (16ax-OH E1) and
estriol (E3). 2-Hydroxylation yields the cat-
echol estrogen 2-hydroxyestrone (2-OH
E1) (36). P450 multisubstrate monooxyge-
nases catalyze the oxidative metabolism of
estrogens, and estrogen 2- and 16a-hydrox-
ylases play a major role in the metabolism
ofthese estrogens (37). E2 is also converted
to catechol estrogen, postulated to arise
from E2 via the 4-hydroxylation pathway,
which is similar to the 2-hydroxylation
pathway (38). The catechol estrogens e.g.,
2-OH E1, 2-hydroxyestradiol (2-OH E2),
and 4-hydroxyestradiol (4-OH E2) seem to
be further oxidized to quinones that cova-
lently bind to DNA (39).
We examined the transforming activity
ofthese estrogens using the SHE cell assay
system. Treatment ofSHE cells with E1, E2,
16a-OH E1, 2-OH E1, or 2-OH E2 induces
morphological transformation ofcells in a
dose-related manner. Exposure to E3 fails to
elicit SHE cell transformation (unpublished
data). Higher transforming activity is
observed in cells treated with 166a-OH E1
or 2-OH E1, when compared to other estro-
gens. 16a-OH E1 could be capable of
inducing UDS and anchorage-independent
growth in mouse mammary epithelial cells
(40). Additionally, 16a-OH E1 binds cova-
lently not only to nucleohistones in vitro
(41), but also to nudear regulatory proteins,
specifically the estrogen receptor, in estrogen
target cells (42). This may disturb normal
gene functions, possibly participating in the
transformation process (41). Elevated levels
of 16x-hydroxylation are detected in breast
tissue from women with breast cancer (43)
and in mouse strains with a high incidence
ofmammary tumor formation (44). How-
ever, the high frequency ofmorphological
transformation ofcells induced by 2-OH E1
could be due to genotoxicity of2-OH E1 or
its metabolites converted in SHE cells,
because treatment with 2-OH E1 induces
chromosome aberrations in SHE cells
(unpublished data). E2 induces morphologi-
cal transformation ofBALB/c 3T3 cells, a
mouse fibroblast cell line having 2- and
4-hydroxylase activity. The transformation
efficiency does not increase with increasing
hormonal potency ofthe estrogens exam-
ined, but correlates well with the relative
rates ofcatechol estrogen formation (45).
Tamoxifen, toremifene, and ICI
164,384 are positive in the SHE cell trans-
formation assay as well (46). Tamoxifen, a
triphenylethylene nonsteroidal antiestrogen,
is a structural analogue ofDES and exerts
mixed or partial agonist/antagonist effects
with estrogens. Toremifene is a new tri-
phenylethylene nonsteroidal antiestrogen; its
molecular structure closely resembles that of
tamoxifen. Toremifene differs from tamox-
ifen by the presence ofa chlorine atom at
the end ofthe ethyl side chain. ICI 164,384
is the 7a-alkylamide analogue ofE2, and a
new steroidal antiestrogen with complete
pure antagonistic properties (47). The
results confirm that hormonal effects are not
implicated in cell transformation. Rather, a
role for estrogen metabolism seems to be
important in estrogen-induced cell transfor-
mation or carcinogenesis. No reports on the
cell transforming activity and carcinogenic-
ity ofother estrogen blockers, e.g., EM 800
and ICI 182,780, are available.
Mechanisms of Cell
Transformation by
Estrogens
AneuploidyInduction
DES induces numerical chromosome
changes (aneuploidy) in SHE cells (20).
The aneuploidy induction occurs at non-
toxic doses and correlates with the ability to
induce cell transformation with parallel
dose-response curves. Treatment of syn-
chronized cultures with DES results in a
cell cycle-dependent induction ofaneuploid
cells that parallels the induction of cell
transformation, with the greatest level
observed following treatment during mito-
sis. Parallel dose-response curves for cell
transformation and aneuploidy induction
by DES are observed when the synchro-
nized cultures are treated during the mitotic
phase of the cell cycle (20). A nonrandom
chromosome gain accompanies DES-
induced immortalization and tumorigenic
conversion ofSHE cells (48). These suggest
that DES-induced aneuploidy is mechanis-
tically involved in estrogen-induced cell
transformation and possibly in carcinogene-
sis (7,22). E2 also induces adose-dependent
increase in the frequencies of aneuploid
cells, corresponding to the inducibility of
morphological transformation (23).
E2 and DES bind and disrupt polymer-
ization of microtubules in cultured mam-
malian cells (49-53). DES inhibits in vitro
assembly of microtubules purified from
porcine brain (54), and induces a decrease
in the number ofspindles and cytoplasmic
microtubule fibers in SHE cells (49) and
Chinese hamster V79 cells (50). E2 has no
ability to interact with microtubules or
Environmental Health Perspectives - Vol 105, Supplement 3 * April 1997 620GENOTOXIC MECHANISMS OF ESTROGENS
microtubule protein in vitro (54), but the
quinone metabolites ofboth E2 and DES
bind covalendy to the C-terminal regions of
P-tubulin, which are important in regula-
tion ofmicrotubule assembly and disruption
(55). E2 exhibits microtubule-disrupting
activity both in estrogen receptor-positive
and receptor-negative human breast cancer
cell lines (51). The disrupting activity is
demonstrated also in V79 cells (51,52),
which have little capability ofmetabolizing
xenobiotics (56). These findings suggest
that E2 itselfinduces microtubule disruption
independent of its binding to estrogen
receptor. Therefore, E2-induced micro-
tubule disruption in living cells seems to be
due to a more complex involvement with
factors regulating microtubule assembly,
such as Ca2+, microtubule accessory pro-
teins, the calcium regulatory protein
calmodulin, adenylate cyclase, or the protein
kinases activated by the cyclic nucleotides
(57-59). Microtubule-disrupting activities
ofE2 and its metabolites in living cells vary
with their chemical structures. Aizu-Yokota
et al. (53) have examined the activity in
V79 cells by the indirect immunofluores-
cence method usinganti-,B-tubulin antibody
and determined the rank-order of the
potencies as follows: E2 2-OH E2 > 4-OH
E2 > 16a-OH E1 = 2-OH E1 > El
= E3.
16a-OH E1 and 2-OH E1 exhibit activities
about one-fourth to one-fifth that ofE2.
The disruptive activities ofE1 and E3 are
negligible when compared to that ofE2.
Functional or conformational change in
microtubule organization could lead to
chromosomal nondisjunction, aneuploidy
induction, and cell transformation.
Tamoxifen, toremifene, and ICI 164,384
induce aneuploidy in SHE cells with no
increases in the frequency ofchromosome
aberrations (46). Tamoxifen binds to cal-
modulin and acts as acalmodulin antagonist
(60). Sargent et al. (61) reported that both
unipolar spindles and incompletely elon-
gated spindles were observed in cultured
hepatocytes from rats treated with tamoxi-
fen, as well as in calmodulin-defective
mutants in yeast (62). Some calmodulin is
associated with the spindle pole body and
plays an important part in the proper func-
tion ofmitotic spindles (62). Tamoxifen-
induced aneuploidy may be due to the
inhibitoryeffect ofcalmodulin bytamoxifen.
Formation ofMicronudei
Both DES and E2 induce the formation of
micronuclei (MN) in cultured mammalian
cells (63-67). MN enclose acentric chro-
mosome fragments or whole chromosomes
that do not become incorporated into the
main nuclei after cell division. MN are
believed to arise from acentric chromoso-
mal fragments or from chromosomes lag-
ging at anaphase resulting from mitotic
disturbance (68). MN packing acentric
chromosomal fragments appear to be
induced byclastogens, while MN enclosing
whole chromosomes are induced by agents
that affect the mitotic apparatus. The
majority ofDES-induced and E2-induced
MN contains whole chromosomes, which
are demonstrated both with antikineto-
chore antibodies and with the centromere-
specific DNA probe (67). DES may need
peroxidative activation to produce metabo-
lite(s) that induce MN, because both DES
oxidation and MN induction by DES are
markedly decreased by indomethacin, an
inhibitor of prostaglandin H synthase
activity (66,69). E2 may require metabolic
activation for MN induction as well, as
indicated by the following: a) 2-OH E2, an
E2 metabolite converted by 2-hydroxylase,
binds covalently to tubulin in vitro with or
without peroxidative activation system
(55), but E2 itself does not; and b) E2
exhibits comparable MN induction to
DES in SHE cells (64), which have both
oxidative (28) and peroxidative activities
(29). Schnitzler et al. (67) have shown that
the mechanism of DES-induced MN is
different from that of E2-induced MN
using SHE cells and ovine seminal cells.
DES-induced MN can arise through chro-
mosome nondisjunction due to spindle dis-
ruption, whereas E2 at the concentrations
used in the MN assay exerts no detectable
effect on the formation ofthe mitotic spin-
dle, but causes chromosome dislocation,
probably due to a functional loss of the
mitotic apparatus.
Genotoxicity
Although DES is not genotoxic in many
assays, in certain studies DES has been
found to induce UDS (21,70-72), sister
chromatid exchanges (73-75), chromo-
some aberrations (76,77) and gene muta-
tions (33,78). The positive studies ofDNA
damage by DES use either cultured mam-
malian cells with exogenous metabolic acti-
vation or cells with possible endogenous
activation capacity for DES. Therefore, we
directly compared the cell transforming
activity and genotoxicity of DES in the
same cells with and without exogenous
metabolic activation. When SHE cells are
treated in the absence of a rat liver PMS-
metabolic activation system, DES fails to
induce DNA damage in SHE cells at doses
that induce cell transformation (7,19,20,
21,33). However, treatment of SHE cells
with DES in the presence ofan exogenous
metabolic activation system enhances the
frequency ofmorphological transformation
of the cells. Furthermore, this treatment
elicits UDS and gene mutations in the cells
at the Na+/K+-ATPase locus (33). Thus,
we have proposed two potential mecha-
nisms for estrogen-induced cell transforma-
tion; in one the target ofthe estrogen is not
DNA but rather microtubule disruption
and the other is associated with DNAdam-
age (33). Both pathways may involve
active genotoxic metabolites ofDES.
DNAAdductFormation
Cellular DNAdamage induced by chemicals
can be examined by detection of DNA
adduct formation through a covalent mod-
ification ofDNA. Liehr et al. (79) demon-
strated the presence of covalent DNA
adducts in premalignant kidneys ofSyrian
hamsters treated chronically with DES
using a sensitive 32P-postlabeling assay.
Because structurally diverse estrogens
induced identical DNA adducts, they con-
cluded that estrogens induce binding ofthe
same unknown endogenous compounds to
target tissue DNA. They also reported that
a distinct pattern of DNA adducts was
detected in the liver, kidney, uterus, and
testes of Syrian hamsters following treat-
ment with DES (80), and the major
adducts found were similar to those pro-
duced by reaction of diethylstilbestrol-
4',4"-quinone with DNA (39). This
suggests that DES acts as a genotoxic car-
cinogen via its metabolic activation to the
electrophilic 4',4"-quinone (39). There is
another possible mechanism bywhich DES
may cause DNA damage. Microsome-
mediated redox cycling between DES or its
catechol and the corresponding quinones
generates superoxide radicals (02--) and
hydroxyl radicals (OH) (81-84). Free
radicals generated by the redox cycling of
DES also oxidize 2'-deoxyguanosine to
8-hydroxy-2'-deoxyguanosine (8-OH-dG)
in vitro (85) as well as in vivo (86). Small
DNA adducts such as 8-OH-dG could be
a causal basis for DES-induced DNA dam-
age, which is detected as gene mutations
and UDS in cultured SHE cells (21,33).
Chronic exposure ofSyrian hamsters to
E2 for 6 months induces renal tumors (6),
and the treatment causes covalent DNA
alterations (adduct formation) in the kid-
ney (82). E2 is metabolically oxidized to
catechol estrogens (2-OH E2 and 4-OH
E2), which are postulated to be capable of
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redox cycling (84). Free radical-mediated
DNA damage might be involved in E2
carcinogenesis because 8-OH-dG levels
increase in kidney DNA ofmale Syrian
hamsters in chronic treatmentwith E2 (87).
To siudy the possible involvement of
DNA damage in cell transformation
induced by estrogens, we have examined
whether DNA adduct formation is elicited
in SHE cells treated with estrogens and
their metabolites by means ofthe nudease
P1 enhancement version of32P-postlabel-
ing (30). DNA adduct formation is
detected in SHE cells treated with DES,
but not in SHE cells treated with trans,
trans-dienestrol (a-dienestrol) or ,B-diene-
strol. Similarly, morphological transforma-
tion ofSHE cells is induced by DES, but
not by a- or 0-dienestrol. Treatment of
SHE cells with DES in the presence of
exogenous metabolic activation with rat
liver PMS enhances morphological trans-
formation in a dose-dependent manner.
Exposure of SHE cells to DES under the
same conditions with exogenous metabolic
activation induces somatic mutations and
UDS. However, following this treatment,
DNA adduct formation is not detected in
SHE cells. It is possible that DNA adducts
may be formed but not detected because
of the instability of the adducts (39).
However, this is unlikely because DNA
adduct formation is not detected even
when SHE cells are treated with DES for
30 min (30). Exposure ofSHE cells to E2
and its metabolites, 2-OH E2 and 4-OH
E2, for 24 hr leads to covalent DNA
adduct formation, corresponding to the
induction ofcell transformation (30). The
results indicate that estrogens induce DNA
adduct formation in cultured SHE cells,
but the induction may not be the only
mechanism relevant to the initiation ofcell
transformation. Because DES and E2 result
in DNA adduct formation and aneuploidy
in SHE cells, the possibility exists that
DNA adduct formation is involved in
nondisjunction leading to aneuploidy.
Alternatively, DNA adduct formation may
only correlate with other adducts in differ-
ent critical macromolecules, such as tubu-
lin (55,88,89), and may not be causally
involved in either morphological transfor-
mation or aneuploidy induction.
E2 is metabolically oxidized to catechol
estrogens that are also postulated to be
capable ofredox cycling, which would gen-
erate free radicals by redox cycling between
2- or 4-OH E2 and their corresponding
quinones (82). Roy et al. (86) showed that
8-OH-dG levels increase in kidney and
liver DNAs of male Syrian hamsters
by chronic treatment with DES but not
with E2. This suggests the involvement of
different mechanisms in cell transformation
induced by DES and E2.
In summary, estrogens (DES and E2)
and their metabolites induce morphological
transformation of SHE cells in a dose-
related manner. DES and E2 do not cause
significant increases in the chromosome
aberrations in SHE cells, but induce numer-
ical chromosome changes in the near
diploid range, corresponding to the trans-
forming activity. In addition, these estro-
gens result in DNA adduct formation in
SHE cells. It has not been dear which cyto-
genetic endpoints are more correlated on a
causal basis with the estrogen-induced cell
transformation. Moreover, other effects by
estrogens, e.g., covalent binding to proteins
(55,88,89) and generation ofreactive oxy-
gen species (39,81,83,84,86) could partici-
pate into inducing transformed cells.
Furthermore, we cannot rule out the possi-
bility that multiple effects ofestrogens act
together to cause genetic alterations leading
to cell transformation. Our studies do, how-
ever, suggest that estrogens have the ability
to directly transform cells bymultiple muta-
genic mechanisms unrelated to estrogenic-
ity. These estrogen-induced changes, in
conjunction with epigenetic changes medi-
ated through the estrogen receptor, may
contribute to hormonal carcinogenesis.
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